2016 Fiscal Year Final Research Report
Bone invasion-targeted chemotherapy with Novel Anionic Platinum Complex (3Pt) in the Treatment of oral squamous cell carcinoma
| Project/Area Number |
26670739
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KASAHARA yoshiya 金沢大学, 大学附属病院, 医員 (00707573)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 頭頸部癌 / シスプラチン / drug delivery system |
|---|
| Outline of Final Research Achievements |
Cisplatin (CDDP) has been a key drug for chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC). Nephrotoxicity and lack of effect on bone invasion are weakness of CDDP. To increase its antitumor effects on bone invasion and reduce such toxicity problems, anionic CDDP (3Pt) have been developed. This study aimed to characterize the basis of the platinum cytotoxicity of novel platinum complex 3Pt in comparison with that of cisplatin for oral squamous cell carcinoma. To investigate the antitumor and nephrotoxic effects of 3Pt, nude mice bearing OSC-19 were administered 3Pt or CDDP. Both 3Pt and CDDP showed equivalent antitumor effects in vivo. Mice with CDDP developed renal cell apoptosis; however, those injected with 3Pt were almost free of renal cell injury. Moreover, in a bone invasion cancer model using OSC-19, 3Pt decreased the volumes of bone resorption than CDDP.
|
| Free Research Field |
頭頸部腫瘍
|
